HIV Conserved Epitopes and Binding Proteins for Viral Entry Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HIV infection, such as anti-retroviral therapies, primarily focus on preventing viral proliferation rather than neutralizing the virus from entering host cells, and there is a lack of clinically approved neutralizing antibodies or antibody-based treatments.
Innovation Solution
Development of highly conserved antigens and epitopes of HIV gp41 and gp120 proteins, along with binding proteins like antibodies, that specifically target these regions to prevent HIV from binding to host cells, and their use in vaccines and diagnostic kits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-retroviral treatments are used to prevent viral proliferation, then viral replication is inhibited, but the virus can still enter host cells and current treatments cannot effectively neutralize the virus
Solution Approach 1:
The patent applies preliminary action by developing binding proteins and vaccines that prevent HIV from binding to CD4+ host cells in the first place. The conserved epitopes on gp120 and gp41 are targeted before viral entry occurs, blocking the virus's ability to infect cells rather than addressing proliferation after infection has established.
Solution Approach 2:
The patent uses binding proteins (antibodies or antibody fragments) as intermediary agents that mediate between the HIV virus and host CD4+ cells. These binding proteins block the direct interaction between viral gp120/gp41 and host cell receptors, preventing viral entry without requiring the virus to actually infect the cell.
2Reliability
If monoclonal antibodies are designed to prevent virus binding to CD4+ cells, then neutralization is achieved, but no clinically approved neutralizing antibodies or antibody-based treatments exist yet
Solution Approach 1:
The patent applies parameter changes by identifying and targeting highly conserved epitopes on HIV gp120 and gp41 proteins. By focusing on conserved regions that remain identical across different HIV strains and variants, the binding proteins achieve broad neutralization capability against diverse viral types, improving the reliability of the treatment approach.
Solution Approach 2:
The patent achieves universality by designing binding proteins that target conserved epitopes common to multiple HIV variants and strains. The conserved nature of these epitopes allows a single binding protein design to provide multi-functional protection against diverse HIV types, including different subtypes and variants, thereby improving clinical applicability.
3Adaptability or versatility
If conserved epitopes are targeted for vaccine development, then broad protection against HIV variants is achieved, but the complexity of identifying and validating conserved regions increases
Solution Approach 1:
The patent applies copying by using computational models and sequence alignments to create simplified representations of conserved epitopes. Instead of analyzing every possible viral protein region, the patent copies and focuses on the critical conserved epitopic regions that are most important for viral entry, thereby reducing the complexity of the search space while maintaining broad protective coverage.
Data Source
AI summary
Provided are highly conserved antigens and epitopes of HIV that can be used in vaccines and to produce bindings proteins (e.g., antibodies) for detecting, treating, preventing, or reducing the risk of HIV infection and the development of AIDS.